T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase.
about
Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditionsA role for tissue transglutaminase in alpha-gliadin peptide cytotoxicityAnimal models to study gluten sensitivityCurrent and emerging therapy for celiac diseaseProperties of Gluten Intolerance: Gluten Structure, Evolution, Pathogenicity and Detoxification CapabilitiesMonitoring of in vitro deamidation of gliadin peptic fragment by mass spectrometry may reflect one of the molecular mechanisms taking place in celiac disease development.Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides.Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process.Gliadin and tissue transglutaminase complexes in normal and coeliac duodenal mucosa.Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac diseaseExtracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury.Parallels between pathogens and gluten peptides in celiac sprueAnalysis of wheat prolamins, the causative agents of celiac sprue, using reversed phase high performance liquid chromatography (RP-HPLC) and matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS).Identification of gliadin-binding peptides by phage display.Review article: coeliac disease, new approaches to therapy.The immune recognition of gluten in coeliac disease.Prevention measures and exploratory pharmacological treatments of celiac disease.Celiac disease: a disorder emerging from antiquity, its evolving classification and risk, and potential new treatment paradigms.Coeliac disease: dissecting a complex inflammatory disorder.An immunodominant DQ8 restricted gliadin peptide activates small intestinal immune response in in vitro cultured mucosa from HLA-DQ8 positive but not HLA-DQ8 negative coeliac patients.T cells in peripheral blood after gluten challenge in coeliac disease.Investigation of the putative immunodominant T cell epitopes in coeliac disease.Transglutaminase 2 inhibitors and their therapeutic role in disease states.Innate and adaptive immunity: the yin and yang of celiac disease.Future therapeutic options for celiac disease.Emerging therapeutic options for celiac disease: potential alternatives to a gluten-free diet.The propensity for deamidation and transamidation of peptides by transglutaminase 2 is dependent on substrate affinity and reaction conditions.Potential of transglutaminase 2 as a therapeutic target.Enzymatic strategies to detoxify gluten: implications for celiac disease.Pharmacotherapy and management strategies for coeliac disease.New clues in celiac disease epidemiology, pathogenesis, clinical manifestations, and treatment.The adaptive immune response in celiac disease.Future treatment strategies for celiac disease.The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet.Targeted modification of wheat grain protein to reduce the content of celiac causing epitopes.Recent advances in the development of new treatments for celiac disease.Advances in the treatment of coeliac disease: an immunopathogenic perspective.Current status of drugs in development for celiac disease.Transglutaminase as a therapeutic target for celiac disease.Emerging drugs for celiac disease.
P2860
Q24658242-D7C52C9A-5E71-42E9-B22E-E779E0E93F50Q24683342-5526D263-1DA5-4C0D-A98A-61B15C342E77Q26859130-154E150B-5377-40C4-8C22-7F102B94FAB1Q27014843-F9859148-FA1A-48A1-B4AA-4EAE5AFE9BB5Q28072666-CE5989A6-ECE9-4DFF-97B2-EBCAE9D9A865Q30835927-A12A6A9E-D398-494F-B357-F76097786516Q31038697-CF2A2CF8-73A9-4A7D-9F6C-84DE2316BE5BQ31091532-D86F392D-ECD2-4469-B2F3-979D0C67E5F5Q33195266-16CCEF74-82DC-4483-A576-558B2785A2DEQ33285135-087B7547-A9D8-40F8-A6D4-D983CDFF512DQ33325485-3B96B788-E94A-4811-95CF-2E9A2B2C1934Q33329537-2B0B30FF-3D00-45AD-AEC6-9C0D02C19A21Q33570451-2E571C53-58C2-4E94-B652-7071596E33FDQ33823074-B5F044FC-EB27-423D-824C-88B5D63E2806Q34253519-98E7A566-9D81-453C-9612-0A4823BFBD7AQ34423420-EFA42734-01FC-4D88-84F7-8539A91CA054Q34623902-E6A027F4-6E08-4E91-9005-C3A7125A11B7Q34809320-1A06F2A1-4A27-4EA1-9856-2543475FA056Q34810240-F7EE00A1-66D9-4BD2-998A-57004C80A17CQ35595364-E7D59CC1-F4BA-400B-B9F2-722D49781E64Q35597668-447727B9-EDAA-4BF0-9ED2-7DC1600BA409Q35598350-F1EF7986-6112-48BD-8456-70D4B0DBCF3BQ35989247-0EF7817E-70BD-4352-BC4C-B464055A46D5Q36209729-5307454B-3C5B-44D5-A5F7-ED3CD57DD87AQ36304110-17576445-69C2-4CD1-8829-B613C4A8F8F2Q36676716-2197F8BD-3106-4C54-A892-667DD067EAE9Q37061772-3857F024-2CE6-4450-BA59-D541CAD842CEQ37776508-3169A6AD-2EDB-4CF6-89B4-B4C90CE322DEQ37806959-AD294F82-646E-4D21-AB12-CD829CDB0E80Q37896092-13A48E36-6358-4370-AD63-8E7C5B5D7BDCQ37905046-0FBE5519-E067-42AC-BE94-0828214DDA34Q38005620-8E93B8C0-97CC-41D4-A12A-D98D98D29A32Q38012460-B799138E-63F3-4160-9336-863DF03F84CFQ38016781-8DA34AEC-A47C-4707-9668-E172F2AA3E1AQ38021639-F1B889ED-5634-49D4-AFF3-953B6E5774B7Q38038684-183842A1-98E8-40E3-873E-2957D2F4F911Q38126789-B654D690-74A3-4FDF-B1B2-17818F669251Q38210088-D042F3D3-1908-4705-9535-FB5A78B7DD01Q38269678-51CAE7FE-AE5E-4D05-A6C5-429BA1FB242CQ38286185-07CCB88A-B90A-4DC2-802C-BB20B9902324
P2860
T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
T cells from celiac disease le ...... enous tissue transglutaminase.
@en
T cells from celiac disease le ...... enous tissue transglutaminase.
@nl
type
label
T cells from celiac disease le ...... enous tissue transglutaminase.
@en
T cells from celiac disease le ...... enous tissue transglutaminase.
@nl
prefLabel
T cells from celiac disease le ...... enous tissue transglutaminase.
@en
T cells from celiac disease le ...... enous tissue transglutaminase.
@nl
P2093
P1476
T cells from celiac disease le ...... enous tissue transglutaminase.
@en
P2093
Arentz-Hansen H
Kristiansen C
P304
P356
10.1002/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I
P407
P577
2001-05-01T00:00:00Z